	US 12,109,189 B2
	CDC7 kinase inhibitors and uses thereof
Mark G. Frattini, Ridgewood, NJ (US); Hakim Djaballah, Scarsdale, NY (US); and Thomas J. Kelly, New York, NY (US)
Assigned to SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, New York, NY (US)
Filed by SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, New York, NY (US)
Filed on Apr. 24, 2023, as Appl. No. 18/138,351.
Application 18/138,351 is a continuation of application No. 17/330,957, filed on May 26, 2021, granted, now 11,666,550.
Application 17/330,957 is a continuation of application No. 16/189,780, filed on Nov. 13, 2018, granted, now 11,045,446, issued on Jun. 29, 2021.
Application 16/189,780 is a continuation of application No. 15/728,609, filed on Oct. 10, 2017, granted, now 10,123,992, issued on Nov. 13, 2018.
Application 15/728,609 is a continuation of application No. 15/349,905, filed on Nov. 11, 2016, granted, now 9,782,386, issued on Oct. 10, 2017.
Application 15/349,905 is a continuation of application No. 14/936,472, filed on Nov. 9, 2015, granted, now 9,492,427, issued on Nov. 15, 2016.
Application 14/936,472 is a continuation of application No. 13/583,170, granted, now 9,180,105, issued on Nov. 10, 2015, previously published as PCT/US2011/027619, filed on Mar. 8, 2011.
Claims priority of provisional application 61/311,741, filed on Mar. 8, 2010.
Prior Publication US 2023/0255929 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/365 (2006.01); A61K 9/00 (2006.01); A61K 31/122 (2006.01); A61K 31/352 (2006.01); A61N 5/10 (2006.01); C07D 493/08 (2006.01); C07D 493/18 (2006.01); C09B 13/02 (2006.01); C09B 61/00 (2006.01); C12Q 1/6886 (2018.01)

CPC A61K 31/365 (2013.01) [A61K 9/0019 (2013.01); A61K 31/122 (2013.01); A61K 31/352 (2013.01); A61N 5/10 (2013.01); C07D 493/08 (2013.01); C07D 493/18 (2013.01); C09B 13/02 (2013.01); C09B 61/00 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)]

18 Claims

1. A method for treating a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the Formula (A-2):

or a pharmaceutically acceptable salt thereof,

wherein:

each instance of R¹and R⁴is independently selected from the group consisting of hydrogen, carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl;

each instance of R²and R³is independently selected from the group consisting of hydrogen, halogen, —OH, substituted hydroxyl, —SH, substituted thiol, —NH₂, substituted amino, —CN, —NO₂, carbonyl, silyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R²and R³are joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl group;

R⁷is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl,

with the proviso that the compound cannot be: